Establishing National Priorities for Clinical Practice Guidelines in Australia
Dr Ann Jones and Dr Martin Whitely made a submission on behalf of the HCC to the Australian Commission on Safety and Quality in Health Care regarding Australian disease treatment guideline development. The submission recommended that before any topics are prioritised for guideline development, there needs to be standardised processes to ensure the integrity of guidelines. The submission stressed the need for transparency, and independent robust evidence in guideline development processes.
Transcript of Senate Select Committee on Health Hearing
Dr Martin Whitely and Dr Ann Jones gave evidence at a Senate Select Committee on Health on 10 October 2014. Their appearance before the committee was to provide further information on the HCC submission to the Committee on the need for reforms to the way pharmaceuticals are regulated. Martin was also able to expand on concerns that the PBS and TGA often act in the best interest of pharmaceutical companies at the expense of health consumers.
For a full transcript of the hearing click on the link.
Preparted by Dr Martin Whitely Manager of Policy and Research